RECRUITING

Biology of Juvenile Myoclonic Epilepsy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.

Official Title

Biology of Juvenile Myoclonic Epilepsy

Quick Facts

Study Start:2017-07-13
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03400371

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:10 Years to 40 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of Juvenile Myoclonic Epilepsy in accordance with Consensus criteria
  2. * Age of myoclonus onset 10-25 years
  3. * Seizures comprising predominant or exclusive early morning myoclonus of upper extremities
  4. * EEG interictal generalized spikes and/or polyspike and waves with normal background
  5. * Current age 10-40 years
  1. * Myoclonus only associated with carbamazepine or lamotrigine therapy
  2. * EEG showing predominant focal interictal epileptiform discharges or abnormal background
  3. * Any evidence of progressive or symptomatic myoclonus epilepsy or focal seizures
  4. * Global learning disability
  5. * Dysmorphic syndrome
  6. * Unable to provide informed consent

Contacts and Locations

Study Contact

Deb K Pal, MD PhD
CONTACT
+442078480608
deb.pal@kcl.ac.uk

Principal Investigator

K Pal, MD PhD
PRINCIPAL_INVESTIGATOR
King's College London

Study Locations (Sites)

Mount Sinai-Beth Israel Medical Center
New York, New York, 10003
United States
St Luke's Roosevelt Hospital
New York, New York, 10025
United States
Nationwide Children's Hospital
Columbus, Ohio, 43125
United States

Collaborators and Investigators

Sponsor: King's College London

  • K Pal, MD PhD, PRINCIPAL_INVESTIGATOR, King's College London

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-07-13
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2017-07-13
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • JME
  • Epilepsy
  • Juvenile Myoclonic Epilepsy
  • Genomewide Association Study
  • Genetics

Additional Relevant MeSH Terms

  • Juvenile Myoclonic Epilepsy